Based on EYS amino acid conservation and the presence of multiple protein-truncating mutations in RP patients [51], we selected human EYS exons 37-41 as a target to assess the therapeutic potential of exon skipping. The gene discussed is EYS; the disease is retinitis pigmentosa 1.